20 May 2013
Keywords: bioton, aims, russian, insulin, market, polish, biotechnology
Article | 25 September 2006
Polish biotechnology company Bioton says that it expects its activities in the Russian drug market to generate between $40.0 million and $50.0
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 September 2006
17 May 2013
© 2013 thepharmaletter.com